Last Updated: Thursday, 18 October 2018
Molecules and bioactivities
S.No Title Inventors and Team Country/Patent No./Grant Date Summary
     
1

Method for the use of alpha artheether as an anti-bacterial and anti-fungal agent

Sushil Kumar,
SPS Khanuja,
TRS Kumar,
DC Jain,
Suchi Srivastava,
AK Bhattacharya,
D Saikia,
AK Shasany,
MP Darokar,
RP Sharma

US/6127405/3.10.2000 The invention relates to the novel use of alpha-arteether as an advanced generation antibacterial and antifungal agent, preferably for bacteria, which are resistant to quinolone drugs due to mutations in DNA gyrase gene
     
2 Benzylidene indanones and processes for preparation and use thereof  AS Negi, 
AP Prakasham,
AK Saxena, 
S Luqman,
D Chanda, 
Tandeep Kaur,
Atul Gupta

US/8633242/21.1.2014

India/291668/12.01.2018

 

The invention relates to the potent anticancer and tubulin polymerization inhibition activity of new benzylidene indanones synthesized from gallic acid against several human cancer cell lines. The invention also provides a new process for the preparation of the said molecules and testing these for in vitro cytotoxic activity against various human cancer cell lines using Sulphorhodamine B Assay. Compounds were evaluated for acute oral activity in Swiss albino mice and were found to be safe up to 300mg/kg body weight.
     
3 A novel plant growth promoting naphthophenone derivative from gallic acid AS Negi,
MP Darokar,
SPS Khanuja,
SK Chattopadhyay,
Ankur Garg,
Togarrati Padmapriya,
Sachin Srivastava,
AK Shasany,
AK Bhattacharya,

SouthAfrica/2006/5368/26.8.2008

India/250039/30.11.2011

This invention provides a plant growth regulatory activity of a new biologically active synthetic molecule Methanone- (3', 4', 5'-trimethoxy) phenyl, 1-naphthyl, 2-O-4'-ethyl but-2'-enoate. More particularly, the invention relates to the potent plant growth promoting activity of a gallic acid derivative having the structural formulae (1) and molecular formulae C26H26O7. This invention also provides a novel process for preparation of a said molecule from a naturally occurring compound and testing it for growth regulating activity using Bacopa test system developed at CIMAP (Khanuja et al 2001).
     
4 A new nitrile glycoside useful as a bioenhancer of drugs and nutrients and the process of its isolation from Moringa oleifera SPS Khanuja,
JS Arya,
TRS Kumar,
D Saikia,
HS Kaur,
Monika Singh,
SC Gupta,
AK Shasany,
MP Darokar,
SK Srivastava,
MM Gupta,
SC Verma,
Anirban Pal
Germany/1611148/5.11.2008

US/6858588/22.2.2005

SouthAfrica/2005/07911/29.11.2006/

India/234974/23.6.2009

The invention relates to a novel nitrile glycoside named NIAZIRIDIN and the analogues and derivatives thereof by bioactivity-guided fractionation from the pods of Moringa oleifera in enhancing bioactivity of commonly used antibiotics such as rifampicin, tetracycline and ampicillin against Gram (+) and (-) bacteria. The biomolecule also enhances the absorption of drugs, vitamins and nutrients through the gastro-intestinal membrane increasing their bio-availability. Therefore, niaziridin can be used in combination therapy with drugs and nutrients resulting in reduced drug associated toxicity, reduced cost and duration of chemotherapy.
 
5 Use of phyllocladane diterpenoids for plant growth promotion and alleviation of growth retardant allelochemicals AK Singh,
GD Bagchi,
Sarita Singh,
PD Dwivedi,
AK Gupta,
SPS Khanuja
Australia/2002348820/14.2.2007

US/6673749/6.1.2004

The invention provides plant growth-promoting activities of active plant constituent calliterpenone and its derivatives belonging to the group phyllocladane diterpenoids. These phytochemicals and derivatives exhibit remarkable growth promoting activities on plant roots, shoots and promote seed germination both in mono and dicotyledonous plants. These phytomolecule possess antagonistic activity against allelochemicals of plant growth retardant nature and hence can be used to alleviate their detrimental effects.
     
 6 Use of the root extract of Vetiveria zizanioides in curing fluoroquinolone and multi drug resistant bacterial infections
SPS Khanuja,
Suchi Srivastava,
TRS Kumar,
MM Gupta,
AK Tripathi,
Monika Singh,
JR Bahl,
RK Lal,
MP Darokar,
AK Shasany,
Sushil Kumar
Canada/2480284/30.6.2013
USA/6676974/13.1.2004
India/218190/31.3.2008
 
The present invention relates to a hexane bioactive fraction obtained from the roots of an aromatic plant named Vetiveria zizanioides commonly found in India for inhibiting the growth of drug-resistant bacterial infections in humans and animals. It also relates to a pharmaceutical composition comprising the bioactive extract with other additives for inhibiting the growth of drug-resistant bacterial infections in humans and animals and a process for the isolation of said bioactive extract.
   
7

a-yohimbine and its derivatives as antipsychotic agents and process of their preparation

SK Srivastava,
VK Khanna,
Shikha Gupta,
AK Agarwal,
Chandishwar Nath,
MM Gupta,
R Kishore Verma

India/281936/29.3.2017

The present invention relates to the development of a virtual screening model for predicting antipsychotic activity using quantitative structure activity relationship (QSAR), molecular docking, oral bioavailability, ADME and Toxicity studies. QSAR model showed activity-descriptors relationship correlating measure (r2) 0.87 (87%) and predictive accuracy of 81% (rCV2=0.81). The present invention specifically showed strong binding affinity of the untested (unknown) novel compounds against anti-psychotic targets viz., Dopamine D2 and Serotonin (5HT2A) receptors through molecular docking approach. The present invention further showed compliance of Lipinski's rule of five for oral bioavailability and toxicity risk assessment for all the active Yohimbine derivatives
 
8 Novel antipsychotic activity in the leaf extracts of Rauwolfia tetraphylla and their useful herbal formulations

SK Srivastava,
AK Agarwal, 
SC Singh, 
VK Khanna, 
Janardan Singh, 
Chandeshwar Nath, 
MM Gupta, 
Shikha Gupta, 
RK Verma, 
Anirban Pal, 
DU Bawankule, 
D Saikia, 
AK Gupta, 
Anupam Maurya,
SPS Khanuja

Australia/2010231489/8.1.2015

US/9018226/28.4.2015

The invention relates to novel antipsychotic activity in the leaf extracts of Rauwolfia tetraphylla and their useful herbal formulations for the treatment of psychosis based on in-vivo validation on animal model and proportional binding affinities for dopaminergic-D2, Cholinergic (muscarinic) and serotonergic (5HT2A) receptors for antipsychotic activity. The invention also provides a process for obtaining antipsychotic extracts from the leaves of Rauwolfia tetraphylla, which are non-toxic and devoid of extra pyramidal side effects.
Hits: 6604